UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
- The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
- You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
- JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005260/en/